Chardan raised the firm’s price target on Taysha Gene Therapies (TSHA) to $9 from $7 and keeps a Buy rating on the shares. After Taysha disclosed details of its FDA-aligned pivotal Part B trial design for its Rett program, the firm said it sees the latest developments as “a favorable outcome for Taysha” and updated its model to increase its view of the Rett odds of success to 45% from 35%, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies 46.9M share Spot Secondary priced at $2.75
- Taysha Gene Therapies price target raised to $6 from $5 at Citizens JMP
- Taysha Gene Therapies Announces Pivotal Trial Design for TSHA-102
- Taysha Gene Therapies announces Part B trial design for TSHA-102
- Taysha Gene Therapies announces common stock offering, no amount given